Given that a randomized trial of 74 patients showed a significant reduction in acute GVHD with tacrolimus and sirolimus, a mTOR inhibitor, compared with tacrolimus and methotrexate [31], further studies will analyze the effect of including MSCs with tacrolimus and sirolimus. This evidence concerns the gene MTOR and acute graft versus host disease.